AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15191512 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection (PAI)
Number of subjects: 310
Study 11135727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 173
Study 11135727 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 173
Study 9820992 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment to lower serum cholesterol
Number of subjects: 4444
Study 9820992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with diastolic dysfunction
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with systolic dysfunction
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with both diastolic and systolic dysfunction
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with preserved diastolic function
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with mild complications (DCI = 2)
Number of subjects: 157
Study 7924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with more severe complications (DCI = 4)
Number of subjects: 157
Study 2572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine prophylaxis (3 g daily for at least 2 years)
Number of subjects: 232
Study 2572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonradical operation
Number of subjects: 232
Study 2572495 — intervention group
Group type: COMPARATOR
Intervention: Radical operation and placebo
Number of subjects: 232
Study 2572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonradical operation and sulfasalazine
Number of subjects: 232
Study 336304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05 mg atropine
Number of subjects: 55
Study 336304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 55
Study 336304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31446844 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS + PLUS intervention delivered over 12 months by a transdisciplinary team including neuropsychologists, occupational therapists, and psychiatrists.
Number of subjects: 0
Study 31446844 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS + PLUS intervention
Number of subjects: 0
Study 31754238 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month daily after-school aerobic exercise program (40 min/day, n=90)
Number of subjects: 175
Study 31754238 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control condition (n=85)
Number of subjects: 175
Study 31718297 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy in addition to optimal medical therapy
Number of subjects: 3984
Study 28103899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative CT (CT group)
Number of subjects: 50
Study 28103899 — intervention group
Group type: COMPARATOR
Intervention: Non-CT group (historical control)
Number of subjects: 50
Study 25457792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 900
Study 25457792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 900
Study 23724771 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed exercise focusing on hip and ankle strength and flexibility, completed over 10 sessions in a 2- to 3-week period.
Number of subjects: 32
Study 22067885 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mm short leg simulation
Number of subjects: 28
Study 22067885 — intervention group
Group type: COMPARATOR
Intervention: NLLD (no leg length discrepancy)
Number of subjects: 28
Study 19765846 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT2x
Number of subjects: 9
Study 19765846 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT1x
Number of subjects: 9
Study 19765846 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMiC/IMRT(MLC)
Number of subjects: 9
Study 19765846 — intervention group
Group type: COMPARATOR
Intervention: 3D‐CRT
Number of subjects: 9
Study 17003303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial pharmacological treatment
Number of subjects: 196
Study 17003303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 17003303 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 196
Study 12770610 — intervention group
Group type: EXPERIMENTAL
Intervention: AIT-082 100 mg/day
Number of subjects: 36
Study 12770610 — intervention group
Group type: EXPERIMENTAL
Intervention: AIT-082 500 mg/day
Number of subjects: 36
Study 12770610 — intervention group
Group type: EXPERIMENTAL
Intervention: AIT-082 2000 mg/day
Number of subjects: 36
Study 12770610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12770610 — intervention group
Group type: EXPERIMENTAL
Intervention: AIT-082 (all doses)
Number of subjects: 36
Study 10932569 — intervention group
Group type: EXPERIMENTAL
Intervention: Monroe's five-step sequence
Number of subjects: 90
Study 10932569 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed five steps
Number of subjects: 90
Study 10932569 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly ordered steps
Number of subjects: 90
Study 10932569 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated message)
Number of subjects: 90
Study 9298381 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous drip infusion for 12-24 hours
Number of subjects: 60
Study 9298381 — intervention group
Group type: COMPARATOR
Intervention: No postoperative intravenous drip infusion
Number of subjects: 60
Study 8362425 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission-computed tomography (SPECT)
Number of subjects: 15
Study 8362425 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value for SPECT graded scale
Number of subjects: 15
Study 3793337 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (CW)
Number of subjects: 6
Study 3793337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 3793337 — intervention group
Group type: COMPARATOR
Intervention: Caffeine ingestion (CC)
Number of subjects: 6
Study 30025392 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 624
Study 30025392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonmetformin users)
Number of subjects: 624
Study 27117440 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (T-sol)
Number of subjects: 558
Study 24642148 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin (0.4mg, three doses: 14 and 2 hours before, and 10 hours after surgery)
Number of subjects: 232
Study 24642148 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232
Study 22181338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg/day for one month (n=10)
Number of subjects: 23
Study 22181338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 23
Study 22181338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 23
Study 20042477 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 20042477 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study 17947726 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m2 twice daily for 2 weeks, followed by a 1-week break) + Erlotinib (150 mg daily)
Number of subjects: 30
Study 17947726 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine + Erlotinib
Number of subjects: 30
Study 15678055 — intervention group
Group type: EXPERIMENTAL
Intervention: TP‐10 (10 mg/kg)
Number of subjects: 59
Study 15678055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12841536 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) therapy, 10-30 mg for the first month and 5-10 mg from the second to the twelfth month.
Number of subjects: 134
Study 12841536 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) with normal serum TSH at the end of the first month of MMI therapy.
Number of subjects: 134
Study 10812235 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (4000 PFU)
Number of subjects: 167
Study 10812235 — intervention group
Group type: COMPARATOR
Intervention: Inactivated VZV vaccine (equal volume to live vaccine)
Number of subjects: 167
Study 10812235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 167
Study 9678125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives started on the first day of menses (day 1 group)
Number of subjects: 100
Study 9678125 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives started on the fifth day after the onset of menses (day 5 group)
Number of subjects: 100
Study 1497039 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (larger dose increments of oxytocin)
Number of subjects: 151
Study 1497039 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (standard dose increments of oxytocin)
Number of subjects: 151
Study 6406448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 60
Study 6406448 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 60
Study 30935341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 33
Study 30935341 — intervention group
Group type: COMPARATOR
Intervention: Trigger point compression
Number of subjects: 33
Study 29497121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg daily
Number of subjects: 183
Study 29497121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 27236887 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Lyophilized Powder (5.2 g in 500 mL normal saline)
Number of subjects: 50
Study 27236887 — intervention group
Group type: COMPARATOR
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 50
Study 24567281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding plastic stent (SEPS) placement
Number of subjects: 52
Study 23479999 — intervention group
Group type: EXPERIMENTAL
Intervention: Furasidine potassium (furamag) 50 mg t.i.d. for 7 days
Number of subjects: 60
Study 23479999 — intervention group
Group type: COMPARATOR
Intervention: Phosphomycin trometamol (monural) 3 g single dose for pulse therapy
Number of subjects: 60
Study 20459883 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole at 5‐15 mg/d
Number of subjects: 207
Study 20459883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 17609404 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 6 months
Number of subjects: 50
Study 15576654 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blockers (RASb) and acetylsalicylic acid (ASA)
Number of subjects: 68
Study 15576654 — intervention group
Group type: COMPARATOR
Intervention: Positive expression of NFkappaB
Number of subjects: 68
Study 12167683 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 277
Study 12167683 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 277
Study 10190876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 21
Study 10190876 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHL patients with phenotype IIB (n=8) during hyperemia
Number of subjects: 21
Study 10190876 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHL patients with phenotype IIB (n=8)
Number of subjects: 21
Study 10190876 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHL patients
Number of subjects: 21
Study 10190876 — intervention group
Group type: COMPARATOR
Intervention: Baseline MBF
Number of subjects: 21
Study 7754886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel cleansing with laxatives and allowed to eat (Group 1)
Number of subjects: 193
Study 7754886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel cleansing with laxatives and liquid supper followed by fasting (Group 2)
Number of subjects: 193
Study 7754886 — intervention group
Group type: COMPARATOR
Intervention: No bowel cleansing and allowed to eat (Group 3)
Number of subjects: 193
Study 7754886 — intervention group
Group type: COMPARATOR
Intervention: No bowel cleansing and liquid supper followed by fasting (Group 4)
Number of subjects: 193
Study 7754886 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxatives before examination (Groups 1 and 2 combined)
Number of subjects: 193
Study 7754886 — intervention group
Group type: COMPARATOR
Intervention: No laxatives (Groups 3 and 4 combined)
Number of subjects: 193
Study 2115298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 35
Study 2115298 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 35
Study 6986827 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg of body weight per day) with prednisone (60 mg per day)
Number of subjects: 16
Study 6986827 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisone (60 mg per day)
Number of subjects: 16
Study 31075401 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem group
Number of subjects: 101
Study 31075401 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatment group (cotrimoxazole 59.5%, quinolones 21.4%)
Number of subjects: 101
Study 31075401 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatment group
Number of subjects: 101
Study 31075401 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem treatment
Number of subjects: 101
Study 30716802 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus voice therapy (Group B)
Number of subjects: 71
Study 30716802 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (Group A)
Number of subjects: 71
Study 26462480 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate 1 mg/month
Number of subjects: 299
Study 26462480 — intervention group
Group type: COMPARATOR
Intervention: Oral risedronate 2.5 mg/day
Number of subjects: 299
Study 24856782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide adjuvanted HNVAC vaccine
Number of subjects: 395
Study 24856782 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted HNVAC vaccine
Number of subjects: 395
Study 24856782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 22114792 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA 510 mg + DHA 340 mg)
Number of subjects: 33
Study 22114792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (850 mg)
Number of subjects: 33
Study 19461257 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular psychotherapy
Number of subjects: 31
Study 19461257 — intervention group
Group type: COMPARATOR
Intervention: Enhanced community treatment
Number of subjects: 31
Study 17257475 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable doser (InnoLet)
Number of subjects: 260
Study 17257475 — intervention group
Group type: COMPARATOR
Intervention: Vial/syringe
Number of subjects: 260
Study 17257475 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for disposable doser
Number of subjects: 260
Study 15542043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurement using DXA
Number of subjects: 363
Study 15542043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content (BMC) measurement using DXA
Number of subjects: 363
Study 15542043 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent volumetric BMD (BMAD) calculation
Number of subjects: 363
Study 15542043 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BMD by socioeconomic status
Number of subjects: 363
Study 11680399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration 1.5 mg/ml plus adrenaline 1/200,000 in normal saline 100 ml
Number of subjects: 60
Study 11680399 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 100 ml plus adrenaline 1/200,000
Number of subjects: 60
Study 9626717 — intervention group
Group type: EXPERIMENTAL
Intervention: B-ERP
Number of subjects: 135
Study 9626717 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ERP
Number of subjects: 135
Study 9626717 — intervention group
Group type: COMPARATOR
Intervention: RELAX
Number of subjects: 135
Study 7946177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine
Number of subjects: 0
Study 7946177 — intervention group
Group type: COMPARATOR
Intervention: Spirapril
Number of subjects: 0
Study 3311191 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of CyA following ATG treatment (group CyA)
Number of subjects: 75
Study 3311191 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including ATG (group STD)
Number of subjects: 75
Study 3311191 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of CyA
Number of subjects: 75
Study 30227780 — intervention group
Group type: EXPERIMENTAL
Intervention: Short femoral stem
Number of subjects: 22
Study 30227780 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional femoral stem
Number of subjects: 22
Study 30227780 — intervention group
Group type: COMPARATOR
Intervention: Control group (66 subjects without hip pathology)
Number of subjects: 22
Study 28994415 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health coaching (PHC)
Number of subjects: 42
Study 26630050 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training tool only (Group B)
Number of subjects: 0
Study 26630050 — intervention group
Group type: COMPARATOR
Intervention: Remote-guidance only (Group A)
Number of subjects: 0
Study 26630050 — intervention group
Group type: COMPARATOR
Intervention: Both RG and computer training tool (Group C)
Number of subjects: 0
Study 25696967 — intervention group
Group type: EXPERIMENTAL
Intervention: remaxol
Number of subjects: 124
Study 25696967 — intervention group
Group type: COMPARATOR
Intervention: basal therapy
Number of subjects: 124
Study 21360528 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference (VC) delivery of cognitive-behavioral anger management treatment (AMT)
Number of subjects: 0
Study 21360528 — intervention group
Group type: COMPARATOR
Intervention: In-person delivery of cognitive-behavioral anger management treatment (AMT)
Number of subjects: 0
Study 18460495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 11
Study 18460495 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index (HGI) diet
Number of subjects: 11
Study 14552179 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐panthenol (5% drops and 5% gel)
Number of subjects: 80
Study 14552179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no D‐panthenol)
Number of subjects: 80
Study 10468503 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐N(G) methyl arginine hydrochloride (L‐NMMA) 6 mg/kg intravenous infusion
Number of subjects: 16
Study 10468503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10468503 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐N(G) methyl arginine hydrochloride (L‐NMMA)
Number of subjects: 16
Study 7782110 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg b.i.d.
Number of subjects: 242
Study 7782110 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin 500 mg/clavulanic acid 125 mg t.i.d.
Number of subjects: 242
Study 2212255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (tobramycin 80 mg and colistin 100 mg, four times daily via gastric tube)
Number of subjects: 181
Study 2212255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal decontamination
Number of subjects: 181
Study 2212255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 345985 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPB
Number of subjects: 145
Study 345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer
Number of subjects: 145
Study 345985 — intervention group
Group type: EXPERIMENTAL
Intervention: Blow bottles
Number of subjects: 145
Study 29996688 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section
Number of subjects: 210
Study 29996688 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal cesarean section
Number of subjects: 210
Study 29781238 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous Preservation Scan (VPS)
Number of subjects: 123
Study 29781238 — intervention group
Group type: COMPARATOR
Intervention: Routine Pre‐Operative Planning Scan (RPOPS)
Number of subjects: 123
Study 27324882 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy plus standard drug treatment
Number of subjects: 50
Study 27324882 — intervention group
Group type: COMPARATOR
Intervention: Standard drug treatment alone
Number of subjects: 50
Study 26354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral right sacral nerve stimulation
Number of subjects: 27
Study 26354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral left sacral nerve stimulation
Number of subjects: 27
Study 26354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sacral nerve stimulation
Number of subjects: 27
Study 23489262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns
Number of subjects: 3
Study 23489262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (UMCG group)
Number of subjects: 3
Study 23489262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (International expert group)
Number of subjects: 3
Study 23489262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (Blistering course group)
Number of subjects: 3
Study 19789937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment (810-nm, 2 W)
Number of subjects: 18